Immutep Announces Investigator-Initiated Phase II Trial Evaluating LAG3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma
Posted: 6 September 2022 Expansion of the efti clinical development pipeline with a new Phase II setting Efti Phase II trial awarded €1.5M (~A$2.2M) in funding as part of the Polish Medical Research Agency program funded by the…
Luina Bio Acquisition Announcement
Posted: 1 September 2022 Dr. Glenn Haifer and Ampersand Capital Partners Acquire Australian Biologics CDMO Luina Bio, Rebranding Company as AcuraBio Brisbane, Australia – 31 August 2022 – AcuraBio (formerly Luina Bio), a leading Australian biopharmaceutical CDMO, has been…
Cloud Based Computing Services – What are the risk management and legal issues for users? – Stephens Lawyers & Consultants
Posted: 30 August 2022 Cloud services can be enablers for a company’s digital transformation. However, understanding the risks and legal issues associated with using cloud services is critical for risk management and protection of an organisation’s data and IP and to…
New Research Grant For Deoxymabs in Metastatic Breast Cancer (Patrys)
Posted: 26 August 2022 Today Patrys announced that the Olivia Newton-John Cancer Research Institute (ONJCRI) has been awarded a $100,000 Victorian State Government Victorian Medical Research Acceleration Fund (VMRAF) grant to support its research investigating the potential for PAT-DX1…
Have your say into a new scale-up and manufacturing facility for biotech and medtech companies
Posted: 25 August 2022 Closing date: 31 August 2022 Translational Manufacturing@TRI (TM@TRI) will serve as Australia’s first purpose built biomedical translational manufacturing facility that will enable biotech and medtech start-up companies to move to the scale-up stage. Construction…
BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited
Posted: 24 August 2022 The Directors of Biotron Limited (‘Biotron’ or ‘the Company’) are pleased to advise that a Phase 2 HIV-1 clinical trial (BIT225-010; ACTRN12621000937819) of its lead antiviral drug, BIT225, is fully recruited. The trial, which…
CLARITY 2.0 COVID-19 Study Concludes Recruitment
Posted: 18 August 2022 Dimerix Limited (ASX: DXB) a biopharmaceutical company with Phase 3 clinical studies in inflammatory diseases currently underway, today confirmed that the CLARITY 2.0 led study of COVID-19 patients has concluded recruitment to allow this…
Biotech companies buck trend that says sector moves slowly
Posted: 15 August 2022 Patience pays off in the biotech world, but the June quarter was pretty fast-moving for a clutch of Australian companies as trials yielded results, patents and manufacturing deals were inked and the odd acquisition…
A reconstructive innovation is giving skin cancer patients another option
Posted: 11 August 2022 PolyNovo Biomaterials Ltd. are delighted to share a new article published as part of the #YourSkin2022 campaign that discusses the innovative application of #NovoSorbBTM for skin cancer patients with complex reconstructive needs. A synthetic dermal…
CSIRO, opens a new lab that will supercharge Australia’s ability to produce vaccines and therapeutics locally
Posted: 11 August 2022 CSIRO, Australia’s national science agency, has opened a new $23.1 million national lab in Melbourne that will bolster the nation’s ability to produce vaccines and drug treatments onshore. Researchers at CSIRO’s National Vaccine and…
Research Australia’s Global Landscape Analysis of Childhood Dementia Research
Posted: 10 August 2022 Research Australia is pleased to partner with the Childhood Dementia Initiative to report on global childhood dementia clinical research: Childhood Dementia Global Landscape Analysis. Research Australia’s report identifies high value-research investment opportunities and emerging…
Genesis Capital invests in Australian firm Crux Biolabs
Posted: 9 August 2022 Genesis Capital is partnering with existing management to expand Crux into new testing and clinical trial streams. Crux Biolabs, a leading Australian laboratory for vaccines, immunotherapies, immuno-oncology and infectious diseases, has announced a significant…
